AHR and esophageal squamous cell carcinoma: In the ESCC context, AHR modulation with the partial AHR agonist 3,3′-diindolylmethane not only down-regulated Vimentin and Slug, but also inhibited the RhoA/ROCK1 pathway, which in turn suppressed COX2/PGE2 signaling, prostaglandin E2 production, migration, metastasis and EMT [174,175,176,177].